Details of Disease

General Information of Disease (ID: DIS38NA0)

• Disease Name: Bone cancer
• Synonyms: osseous tumour; osseous tumor; bone tumour; bone tumor; bone neoplasm; skeletal element cancer; osseous cancer; malignant tumour of the bone; malignant tumour of bone; malignant tumor of the bone; malignant tumor of bone; malignant skeletal element neoplasm; malignant osseous tumour; malignant osseous tumor; malignant osseous neoplasm; malignant neoplasm of the bone; malignant neoplasm of skeletal element; malignant neoplasm of bone; malignant bone tumour; malignant bone tumor; malignant bone neoplasm; cancer of the bone; cancer of skeletal element; cancer of bone; bone cancer; CA - bone cancer
• Disease Class: 2B5Z: Bone cancer
• Definition: A primary or metastatic malignant neoplasm affecting the bone or articular cartilage.
• Disease Hierarchy:
  DIS1EPAM: Musculoskeletal system cancer
  DISAT1Z9: Advanced cancer
  DISPLTKN: Bone neoplasm
  DIS38NA0: Bone cancer
• ICD Code:
  ICD-11: ICD-11: 2B5Z
  Expand ICD-11: '2B5Z
  Expand ICD-10: 'C40-C41; 'C40; 'C41; 'C45.9
• Disease Identifiers:
  MONDO ID: MONDO_0002129
  MESH ID: D001859
  UMLS CUI: C0279530
  MedGen ID: 79002
  SNOMED CT ID: 428281000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID27998201-Compound-12	DM8QZNC	Patented	Small molecular drug	[1]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Samarium-153-DOTMP	DMW486B	Investigative	NA	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 15 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BAP1	TT47RXJ	moderate	Biomarker	[3]
ASIC3	TTLGDIS	Strong	Altered Expression	[4]
CNR2	TTMSFAW	Strong	Biomarker	[5]
CRTC1	TT4GO0F	Strong	Altered Expression	[6]
DPEP1	TTYUENF	Strong	Biomarker	[7]
KCNA2	TTVFB0O	Strong	Altered Expression	[8]
MMP2	TTLM12X	Strong	Biomarker	[9]
NCOA3	TT124R0	Strong	Biomarker	[10]
NMUR2	TT2L6C5	Strong	Biomarker	[11]
OPRM1	TTKWM86	Strong	Biomarker	[12]
P2RX7	TT473XN	Strong	Altered Expression	[13]
PLAU	TTGY7WI	Strong	Biomarker	[9]
PLOD2	TT8MEUD	Strong	Biomarker	[14]
SLC12A5	TTH6UZY	Strong	Biomarker	[15]
TGFBR2	TTZE3P7	Definitive	Therapeutic	[16]

This Disease Is Related to 13 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
EWSR1	OT7SRHV3	Strong	Genetic Variation	[17]
FSIP1	OTYLL6GM	Strong	Altered Expression	[18]
GPR65	OTCF5O4G	Strong	Altered Expression	[19]
MCF2L2	OTOGFMIH	Strong	Biomarker	[20]
OSR1	OTB19LEQ	Strong	Biomarker	[21]
PENK	OT8P3HMP	Strong	Genetic Variation	[22]
RHOBTB2	OT2DATFX	Strong	Biomarker	[23]
SGMS2	OT3NHO99	Strong	Biomarker	[24]
SMC3	OTWGFRHD	Strong	Biomarker	[25]
SUV39H2	OTU0F4LL	Strong	Altered Expression	[26]
SYNPO	OTICDJAB	Strong	Biomarker	[27]
TRAT1	OTMPUNPD	Strong	Biomarker	[28]
TRIM14	OTLQKUG0	Strong	Altered Expression	[29]

References

• [1] Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
• [2] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [3] Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area.Genes Chromosomes Cancer. 2015 Jan;54(1):51-62. doi: 10.1002/gcc.22218. Epub 2014 Sep 18.
• [4] Resveratrol attenuates bone cancer pain through regulating the expression levels of ASIC3 and activating cell autophagy.Acta Biochim Biophys Sin (Shanghai). 2017 Nov 1;49(11):1008-1014. doi: 10.1093/abbs/gmx103.
• [5] Cannabinoid receptor 2selective agonist JWH015 attenuates bone cancer pain through the amelioration of impaired autophagy flux induced by inflammatory mediators in the spinal cord.Mol Med Rep. 2019 Dec;20(6):5100-5110. doi: 10.3892/mmr.2019.10772. Epub 2019 Oct 25.
• [6] CREB-regulated transcription coactivator 1 enhances CREB-dependent gene expression in spinal cord to maintain the bone cancer pain in mice.Mol Pain. 2016 Apr 8;12:1744806916641679. doi: 10.1177/1744806916641679. Print 2016.
• [7] Fibrous Dysplasia of the Rib Mimicking a Malignant Bone Tumor at SPECT/CT with 99mTc-MDP.Clin Nucl Med. 2018 May;43(5):346-348. doi: 10.1097/RLU.0000000000002015.
• [8] DNMT3a contributes to the development and maintenance of bone cancer pain by silencing Kv1.2 expression in spinal cord dorsal horn.Mol Pain. 2017 Jan-Dec;13:1744806917740681. doi: 10.1177/1744806917740681.
• [9] Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. Anticancer Res. 2006 Jan-Feb;26(1A):23-6.
• [10] Overexpression of steroid receptor coactivator-3 in bone cancers: an in vivo immunohistochemical study with tissue microarray.Pathol Res Pract. 2013 Dec;209(12):790-6. doi: 10.1016/j.prp.2013.09.008. Epub 2013 Sep 26.
• [11] The short interference RNA (siRNA) targeting NMUR2 relieves nociception in a bone cancer pain model of rat through PKC-ERK and PI3K-AKT pathways.Biochem Biophys Res Commun. 2019 May 7;512(3):616-622. doi: 10.1016/j.bbrc.2019.03.067. Epub 2019 Mar 23.
• [12] Targeting MOR-mGluR(5) heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5.Neuropharmacology. 2019 Dec 1;160:107690. doi: 10.1016/j.neuropharm.2019.107690. Epub 2019 Jul 1.
• [13] P2X7, a critical regulator and potential target for bone and joint diseases.J Cell Physiol. 2019 Mar;234(3):2095-2103. doi: 10.1002/jcp.27544. Epub 2018 Oct 14.
• [14] Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.Anticancer Res. 2005 Mar-Apr;25(2B):1457-63.
• [15] Suppression of HDAC2 in Spinal Cord Alleviates Mechanical Hyperalgesia and Restores KCC2 Expression in a Rat Model of Bone Cancer Pain. Neuroscience. 2018 May 1;377:138-149.
• [16] Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006 Feb 15;66(4):2067-73.
• [17] PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.Oncotarget. 2015 Oct 6;6(30):28895-910. doi: 10.18632/oncotarget.5000.
• [18] Overexpression of 17-hydroxysteroid dehydrogenase type 10 increases pheochromocytoma cell growth and resistance to cell death.BMC Cancer. 2015 Mar 22;15:166. doi: 10.1186/s12885-015-1173-5.
• [19] TDAG8 involved in initiating inflammatory hyperalgesia and establishing hyperalgesic priming in mice.Sci Rep. 2017 Feb 1;7:41415. doi: 10.1038/srep41415.
• [20] Transcriptional Regulation of Voltage-Gated Sodium Channels Contributes to GM-CSF-Induced Pain.J Neurosci. 2019 Jun 26;39(26):5222-5233. doi: 10.1523/JNEUROSCI.2204-18.2019. Epub 2019 Apr 23.
• [21] Suppression of WNK1-SPAK/OSR1 Attenuates Bone Cancer Pain by Regulating NKCC1 and KCC2.J Pain. 2019 Dec;20(12):1416-1428. doi: 10.1016/j.jpain.2019.05.005. Epub 2019 May 11.
• [22] Antinociceptive Effect of Intrathecal Injection of Genetically Engineered Human Bone Marrow Stem Cells Expressing the Human Proenkephalin Gene in a Rat Model of Bone Cancer Pain.Pain Res Manag. 2017;2017:7346103. doi: 10.1155/2017/7346103. Epub 2017 Feb 14.
• [23] Downregulated RhoBTB2 expression contributes to poor outcome in osteosarcoma patients.Cancer Biother Radiopharm. 2013 Dec;28(10):709-16. doi: 10.1089/cbr.2012.1386. Epub 2013 Jun 18.
• [24] Simultaneous inhibition of NMDA and mGlu1/5 receptors by levo-corydalmine in rat spinal cord attenuates bone cancer pain.Int J Cancer. 2017 Aug 15;141(4):805-815. doi: 10.1002/ijc.30780. Epub 2017 May 29.
• [25] The Ubiquitination of Spinal MrgC Alleviates Bone Cancer Pain and Reduces Intracellular Calcium Concentration in Spinal Neurons in Mice.Neurochem Res. 2019 Nov;44(11):2527-2535. doi: 10.1007/s11064-019-02869-3. Epub 2019 Sep 12.
• [26] Histone methyltransferase SUV39H2 serves oncogenic roles in osteosarcoma.Oncol Rep. 2019 Jan;41(1):325-332. doi: 10.3892/or.2018.6843. Epub 2018 Nov 1.
• [27] Spinal miRNA-124 regulates synaptopodin and nociception in an animal model of bone cancer pain.Sci Rep. 2017 Sep 8;7(1):10949. doi: 10.1038/s41598-017-10224-1.
• [28] Target therapy of TRIM-14 inhibits osteosarcoma aggressiveness through the nuclear factor-B signaling pathway.Exp Ther Med. 2018 Mar;15(3):2365-2373. doi: 10.3892/etm.2017.5679. Epub 2017 Dec 27.
• [29] Bispecific antibody suppresses osteosarcoma aggressiveness through regulation of NF-B signaling pathway.Tumour Biol. 2017 Jun;39(6):1010428317705572. doi: 10.1177/1010428317705572.